News & Updates

Rucaparib significantly improves radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel, abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring BRCA alterations whose disease has progressed after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI), results of the phase III TRITON3 trial have shown.

The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

Postdiagnostic use of low-dose zinc supplement may help reduce the risk of lethal prostate cancer and all-cause mortality among patients with nonmetastatic prostate cancer, suggests a recent study.